Advertisement
Canada markets close in 4 hours 19 minutes
  • S&P/TSX

    22,394.54
    +135.38 (+0.61%)
     
  • S&P 500

    5,202.67
    +15.00 (+0.29%)
     
  • DOW

    39,222.87
    +166.48 (+0.43%)
     
  • CAD/USD

    0.7307
    +0.0019 (+0.26%)
     
  • CRUDE OIL

    79.11
    +0.12 (+0.15%)
     
  • Bitcoin CAD

    84,856.12
    -413.02 (-0.48%)
     
  • CMC Crypto 200

    1,332.98
    +32.88 (+2.53%)
     
  • GOLD FUTURES

    2,339.80
    +17.50 (+0.75%)
     
  • RUSSELL 2000

    2,066.17
    +11.03 (+0.54%)
     
  • 10-Yr Bond

    4.4870
    -0.0050 (-0.11%)
     
  • NASDAQ

    16,339.05
    +36.29 (+0.22%)
     
  • VOLATILITY

    13.15
    +0.15 (+1.15%)
     
  • FTSE

    8,380.61
    +26.56 (+0.32%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • CAD/EUR

    0.6778
    +0.0002 (+0.03%)
     

Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).